Amsterdam Cardiovascular Sciences
-
Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition
Chen, S., Overberg, K., Ghouse, Z., Hollmann, M. W., Weber, N. C., Coronel, R. & Zuurbier, C. J., 1 May 2024, In: Biomedicine and Pharmacotherapy. 174, 116477.Research output: Contribution to journal › Article › Academic › peer-review
-
SGLT2 independent effects of the SGLT2 inhibitor empagliflozin: Focus on the heart
Chen, S., 2024, 221 p.Research output: PhD Thesis › Phd-Thesis - Research and graduation internal
-
Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2
Chen, S., Wang, Q., Christodoulou, A., Mylonas, N., Bakker, D., Nederlof, R., Hollmann, M. W., Weber, N. C., Coronel, R., Wakker, V., Christoffels, V. M., Andreadou, I. & Zuurbier, C. J., 17 Jan 2023, In: Circulation. 147, 3, p. 276-279 4 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications